Canadian Manufacturing

Optimi Health announces CAD $3M in senior debt financing

by CM Staff   

Financing Manufacturing Regulation Risk & Compliance Technology / IIoT debt financing Manufacturing Pharmaceutical Manufacturing


Optimi CFO Jacob Safarik announced that the company plans to allocate the funding towards scaling its operations and fulfilling its on-going supply agreements.

VANCOUVER — Optimi Health Corp., a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA, announces the non-dilutive Debt Financing Agreement and General Security Agreement for proceeds of up to CAD $3,000,000. The company has already brought in the first tranche of CAD $1,000,000 from Catcher Investments Ltd., a company under the stewardship of Mr. JJ Wilson, who also serves as a director and non-executive Chair of Optimi Health.

Pursuant to the Debt Financing Agreement and the GSA, the financing is secured against the assets of the Company and will bear interest at a rate of 7.5% per annum, payable by the Company to the Lender(s) quarterly on the last business day of every fiscal quarter until full repayment. Upon maturity, all outstanding principal shall be payable on August 4, 2026, and the Company may repay the Loan at any time on notice to the Lender(s), subject to a prepayment fee.

From the inception of Optimi in 2020 with co-founders Dane Stevens, Bryan Safarik, and Jacob Safarik, Mr. Wilson has reportedly been a pioneering force in the psychedelic and wellness sector.

“Witnessing Optimi’s commercialization and transformation over a span of three years fills me with immense pride,” expressed Wilson. “As we welcome new investors and opportunities, I remain excited and committed to Optimi’s continued growth on a global scale.”

The Debt Financing Agreement and GSA were approved by the independent members of the Company’s board of directors.

Optimi CFO Jacob Safarik announced that the company plans to allocate the funding towards scaling its operations and fulfilling its on-going supply agreements. Additionally, he added that “the Company continues to expand its in-house GMP capabilities and attract new commercial agreements. Combined with the forecasted revenue, this financing puts Optimi on a path to achieving positive EBITDA.”

Advertisement

Stories continue below